Yi Zheng
Humana Press
e druk, 2016
9781493959006
Rational Drug Design
Methods and Protocols
Specificaties
Paperback, blz.
|
Engels
Humana Press |
e druk, 2016
ISBN13: 9781493959006
Rubricering
Onderdeel van serie
Methods in Molecular Biology
Levertijd ongeveer 8 werkdagen
Samenvatting
Over the past three decades there have been new developments in therapeutic drug design. In Rational Drug Design: Methods and Protocols, expert researchers in the field detail many of the methodologies used to study rational drug design. These include methods such as virtual screening of chemical hits, rational lead discovery by high throughput screening, combinatorial and fragment based lead generation, peptide based drug discovery, and animal models of lead validation. Written in the highly successful Methods in Molecular Biology™ series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and key tips on troubleshooting and avoiding known pitfalls.
Authoritative and practical, Rational Drug Design: Methods and Protocols seeks to aid scientists in the further study of rational drug design and future drug discovery.
Specificaties
Inhoudsopgave
<p>1. On Setting up and Assessing Docking Simulations for Virtual Screening</p><p>Jacek Biesiada, Aleksey Porollo, Jaroslaw Meller</p><p> </p><p>2. Virtual Ligand Screening Combined with NMR to Identify Dvl PDZ Domain Inhibitors Targeting the Wnt Signaling</p><p>Jufang Shan and Jie J. Zheng</p><p> </p><p>3. Rational Design of Rho GTPase Targeting Inhibitors</p><p>Xun Shang and Yi Zheng</p> 4. Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies<p>Wenyong Tong, Tara Sprules, Kalle Gehring, H. Uri Saragovi</p><p> </p><p>5. A Combinatorial Strategy for the Acquisition of Potent and Specific Protein Tyrosine Phosphatase Inhibitors</p><p>Sheng Zhang, Lan Chen, David S. Lawrence and Zhong-Yin Zhang</p><p> </p><p>6. Identification of Allosteric Inhibitors of p21-Activated Kinase</p><p>Julien Viaud and Jeffrey R. Peterson</p> 7. Using a Modified Yeast Two-hybrid System to Screen for Chemical GEF InhibitorsAnne Blangy and Philippe Fort .<p> </p><p>8. Random Mutagenesis of Peptide Aptamers As An Optimization Strategy for Inhibitor Screening</p><p>Nathalie Bouquier, Sylvie Fromont, Anne Debant and Susanne Schmidt</p><p> </p><p>9. A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor</p><p>Tina Shahian and Charles S. Craik</p><p> </p><p>10. Use of a Fluorescent ATP Analog to Probe the Allosteric Conformational Change in the Active Site of the Protein Kinase PDK1</p><p>Valerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi</p> 11. Affinity Purification of Protein Kinases that Adopt a Specific Inactive ConformationPratistha Ranjitkar and Dustin J. Maly 12. Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein KinasesSanjay B. Hari, Pratistha Ranjitkar and Dustin J. Maly<p> </p><p>13. Purification and Specific Assays for Measuring APE-1 Endonuclease Activity</p><p>Adrian Esqueda, Mohammed Z Mohammed, Srinivasan Madhusudan, and Nouri Neamati</p><p> </p><p>14. An in vitro Screening to Identify Drug Resistant Mutations for Target-directed Chemotherapeutic Agents</p><p>Mohammad Azam</p><p> </p><p>15. Utilizing AntagomiR (anti-sense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells</p><p>Chinavenmeni S. Velu and H. Leighton Grimes</p><p> </p><p>16. Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs and Other Therapeutics to Target Cells</p><p>Mathieu Cinier, Yi Shu, Daniel Binzel, and Peixuan Guo</p><p> </p><p>17. Mouse Models for Tumor Metastasis</p><p>Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang<p>1. On Setting up and Assessing Docking simulations for Virtual Screening</p><p>Jacek Biesiada, Aleksey Porollo, Jaroslaw Meller</p><p> </p><p>2. Virtual Ligand Screening Combined with NMR to Identify Dvl PDZ Domain Inhibitors Targeting the Wnt Signaling</p><p>Jufang Shan and Jie J. Zheng</p><p> </p><p>3. Rational Design of Rho GTPase Targeting Inhibitors</p><p>Xun Shang and Yi Zheng</p> 4. Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies<p>Wenyong Tong, Tara Sprules, Kalle Gehring, H. Uri Saragovi</p><p> </p><p>5. A Combinatorial Strategy for the Acquisition of Potent and Specific Protein Tyrosine Phosphatase Inhibitors</p><p>Sheng Zhang, Lan Chen, David S. Lawrence and Zhong-Yin Zhang</p><p> </p><p>6. Identification of Allosteric Inhibitors of p21-Activated Kinase</p><p>Julien Viaud and Jeffrey R. Peterson</p> 7. Using a Modified Yeast Two-hybrid System to Screen for Chemical GEF InhibitorsAnne Blangy and Philippe Fort .<p> </p><p>8. Random Mutagenesis of Peptide Aptamers As An Optimization Strategy for Inhibitor Screening</p><p>Nathalie Bouquier, Sylvie Fromont, Anne Debant and Susanne Schmidt</p><p> </p><p>9. A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor</p><p>Tina Shahian and Charles S. Craik</p><p> </p><p>10. Use of a Fluorescent ATP Analog to Probe the Allosteric Conformational Change in the Active Site of the Protein Kinase PDK1</p><p>Valerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi</p> 11. Affinity Purification of Protein Kinases that Adopt a Specific Inactive ConformationPratistha Ranjitkar and Dustin J. Maly 12. Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein KinasesSanjay B. Hari, Pratistha Ranjitkar and Dustin J. Maly<p> </p><p>13. Purification and Specific Assays for Measuring APE-1 Endonuclease Activity</p><p>Adrian Esqueda, Mohammed Z Mohammed, Srinivasan Madhusudan, and Nouri Neamati</p><p> </p><p>14. An in vitro Screening to Identify Drug Resistant Mutations for Target-directed Chemotherapeutic Agents</p><p>Mohammad Azam</p><p> </p><p>15. Utilizing AntagomiR (anti-sense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells</p><p>Chinavenmeni S. Velu and H. Leighton Grimes</p><p> </p><p>16. Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs and Other Therapeutics to Target Cells</p><p>Mathieu Cinier, Yi Shu, Daniel Binzel, and Peixuan Guo</p><p> </p><p>17. Mouse Models for Tumor Metastasis</p><p>Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang</p><p></p><p>1. On Setting up and Assessing Docking simulations for Virtual Screening</p><p>Jacek Biesiada, Aleksey Porollo, Jaroslaw Meller</p><p> </p><p>2. Virtual Ligand Screening Combined with NMR to Identify Dvl PDZ Domain Inhibitors Targeting the Wnt Signaling</p><p>Jufang Shan and Jie J. Zheng</p><p> </p><p>3. Rational Design of Rho GTPase Targeting Inhibitors</p><p>Xun Shang and Yi Zheng</p> 4. Rational Design of Peptide Ligands Against a Glycolipid by NMR Studies<p>Wenyong Tong, Tara Sprules, Kalle Gehring, H. Uri Saragovi</p><p> </p><p>5. A Combinatorial Strategy for the Acquisition of Potent and Specific Protein Tyrosine Phosphatase Inhibitors</p><p>Sheng Zhang, Lan Chen, David S. Lawrence and Zhong-Yin Zhang</p><p> </p><p>6. Identification of Allosteric Inhibitors of p21-Activated Kinase</p><p>Julien Viaud and Jeffrey R. Peterson</p> 7. Using a Modified Yeast Two-hybrid System to Screen for Chemical GEF InhibitorsAnne Blangy and Philippe Fort .<p> </p><p>8. Random Mutagenesis of Peptide Aptamers As An Optimization Strategy for Inhibitor Screening</p><p>Nathalie Bouquier, Sylvie Fromont, Anne Debant and Susanne Schmidt</p><p> </p><p>9. A Screening Strategy for Trapping the Inactive Conformer of a Dimeric Enzyme with a Small Molecule Inhibitor</p><p>Tina Shahian and Charles S. Craik</p><p> </p><p>10. Use of a Fluorescent ATP Analog to Probe the Allosteric Conformational Change in the Active Site of the Protein Kinase PDK1</p><p>Valerie Hindie, Laura A. Lopez-Garcia, and Ricardo M. Biondi</p> 11. Affinity Purification of Protein Kinases that Adopt a Specific Inactive ConformationPratistha Ranjitkar and Dustin J. Maly 12. Determination of the Kinetics and Thermodynamics of Ligand Binding to a Specific Inactive Conformation in Protein KinasesSanjay B. Hari, Pratistha Ranjitkar and Dustin J. Maly<p> </p><p>13. Purification and Specific Assays for Measuring APE-1 Endonuclease Activity</p><p>Adrian Esqueda, Mohammed Z Mohammed, Srinivasan Madhusudan, and Nouri Neamati</p><p> </p><p>14. An in vitro Screening to Identify Drug Resistant Mutations for Target-directed Chemotherapeutic Agents</p><p>Mohammad Azam</p><p> </p><p>15. Utilizing AntagomiR (anti-sense microRNA) to Knock Down microRNA in Murine Bone Marrow Cells</p><p>Chinavenmeni S. Velu and H. Leighton Grimes</p><p> </p><p>16. Synthesis, Conjugation, and Labeling of Multifunctional pRNA Nanoparticles for Specific Delivery of siRNA, Drugs and Other Therapeutics to Target Cells</p><p>Mathieu Cinier, Yi Shu, Daniel Binzel, and Peixuan Guo</p><p> </p><p>17. Mouse Models for Tumor Metastasis</p><p>Shengyu Yang, J. Jillian Zhang, and Xin-Yun Huang</p><p>